Literature DB >> 34410284

RETRACTED: Expression of Concern: "Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection".

Andrew Hill1, Anna Garratt2, Jacob Levi3, Jonathan Falconer4, Leah Ellis5, Kaitlyn McCann5, Victoria Pilkington6, Ambar Qavi5, Junzheng Wang5, Hannah Wentzel5.   

Abstract

Entities:  

Year:  2021        PMID: 34410284      PMCID: PMC8369353          DOI: 10.1093/ofid/ofab394

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   4.423


× No keyword cloud information.
Open Forum Infectious Diseases, ofab358, https://doi.org/10.1093/ofid/ofab358 Published: 06 July 2021 On July 6, 2021, Open Forum Infectious Diseases published the article “Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection” by Hill, et al. Subsequently, we and the authors have learned that one of the studies on which this analysis was based has been withdrawn due to fraudulent data. The authors will be submitting a revised version excluding this study, and the currently posted paper will be retracted.
  8 in total

Review 1.  Ivermectin for preventing and treating COVID-19.

Authors:  Maria Popp; Stefanie Reis; Selina Schießer; Renate Ilona Hausinger; Miriam Stegemann; Maria-Inti Metzendorf; Peter Kranke; Patrick Meybohm; Nicole Skoetz; Stephanie Weibel
Journal:  Cochrane Database Syst Rev       Date:  2022-06-21

2.  Identification and Development of Therapeutics for COVID-19.

Authors:  Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene
Journal:  mSystems       Date:  2021-11-02       Impact factor: 6.496

3.  Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud.

Authors:  Andrew Hill; Manya Mirchandani; Victoria Pilkington
Journal:  Open Forum Infect Dis       Date:  2022-01-17       Impact factor: 3.835

4.  Correction of scientific literature: Too little, too late!

Authors:  Lonni Besançon; Elisabeth Bik; James Heathers; Gideon Meyerowitz-Katz
Journal:  PLoS Biol       Date:  2022-03-03       Impact factor: 8.029

Review 5.  COVID-19 in Latin America and the Caribbean: Two years of the pandemic.

Authors:  Alvaro Schwalb; Eleonora Armyra; Melissa Méndez-Aranda; César Ugarte-Gil
Journal:  J Intern Med       Date:  2022-04-22       Impact factor: 13.068

6.  A Randomized Controlled Trial of Combined Ivermectin and Zinc Sulfate versus Combined Hydroxychloroquine, Darunavir/Ritonavir, and Zinc Sulfate among Adult Patients with Asymptomatic or Mild Coronavirus-19 Infection.

Authors:  Sireethorn Nimitvilai; Yupin Suputtamongkol; Ussanee Poolvivatchaikarn; Dechatorn Rassamekulthana; Nuttawut Rongkiettechakorn; Anek Mungaomklang; Susan Assanasaen; Ekkarat Wongsawat; Chompunuch Boonarkart; Waritta Sawaengdee
Journal:  J Glob Infect Dis       Date:  2022-06-29

7.  Correction: Cruciani et al. Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis. Diagnostics 2021, 11, 1645.

Authors:  Mario Cruciani; Ilaria Pati; Francesca Masiello; Marina Malena; Simonetta Pupella; Vincenzo De Angelis
Journal:  Diagnostics (Basel)       Date:  2021-12-14

8.  Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients.

Authors:  Marcos Alejandro Mayer; Alejandro Krolewiecki; Alejandro Ferrero; Marcelo Bocchio; Juan Barbero; Marcos Miguel; Ariel Paladini; Carlos Delgado; Juan Ramón Ojeda; Claudia Elorza; Ana Bertone; Pedro Emanuel Fleitas; Gustavo Vera; Mario Rubén Kohan
Journal:  Front Public Health       Date:  2022-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.